GP6 and neoplasm: Further supporting this finding, the repurposing of revacept, a soluble dimeric GPVI-Fc fusion protein developed for the treatment of atherothrombotic diseases, has been demonstrated in a model of colon carcinoma to inhibit aberrant COX-2 expression and tumour EMT (66).